Study of a new drug for high-risk bladder cancer
Part of Cancer, Kidney & urinary, Women’s health & pregnancy clinical trials.
This trial tests a combination of a drug (DV) and BCG immunotherapy for people with high-risk, early-stage bladder cancer that has not spread into the muscle. The cancer must show a specific protein called HER2 on its cells.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must be 18 years or older.
- You must have high-risk, non-muscle-invasive bladder cancer that has a protein called HER2 on its cells.
- All visible tumors must have been recently removed through a procedure called TURBT (a scope through the urethra).
- You must not be able or willing to have your bladder removed surgically.
- You must be in fairly good general health, able to care for yourself most of the time.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new combination treatment (SHR-1501 plus BCG) compared to standard chemotherapy for people with bladder cancer that hasn't responded to BCG. The goal is to see if this combination works better at controlling the cancer.
This study is testing whether a urine or blood test can help guide BCG treatment for high-risk bladder cancer that hasn't spread into the muscle. It is only for people over 65 who are new to BCG therapy.
This study tests a new drug called UGN-501, given directly into the bladder through a catheter, for people whose bladder cancer (non-muscle invasive) has returned after previous treatments. It aims to find the right dose and see if it helps control the cancer.
This trial tests a new form of intravesical (given directly into the bladder) treatment called rMBCG for people with non-muscle invasive bladder cancer who have not had BCG therapy before. It may be an option for those with certain types of early bladder cancer, including carcinoma in situ (CIS) or papillary tumors after removal surgery.
This trial tests a combination of two treatments after bladder tumor surgery: a drug called toripalimab (given through a vein) plus BCG therapy (given into the bladder) for people with high-risk non-muscle-invasive bladder cancer. The goal is to see if this combination can help prevent the cancer from coming back.
This trial tests a new drug (FL115) given directly into the bladder, alone or with BCG, for people with a type of bladder cancer that has not responded to BCG therapy. It aims to find a better treatment option for those who cannot have or refuse bladder removal surgery.
Hear when a new Bladder (Urothelial, Transitional Cell) Cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.